Device Trial Radar · NCT05318417
Investigation to Evaluate the Safety and Effectiveness of Cochlear Implantation in Children and Adults With Unilateral Hearing Loss/Single-sided Deafness
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Aug 19, 2022
Primary completion
May 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- CochlearNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- NAMSA
- First posted
- Apr 8, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to assess the continued efficacy and safety of cochlear implantation in participants aged 5 years and above with Unilateral Hearing Loss (UHL)/Single Sided Deafness (SSD) supporting a change indication for use.
Conditions
- Hearing Loss, Unilateral
- Deafness, Unilateral
Interventions
The Cochlear™ Nucleus® Cochlear Implant (CI) SystemDevice
The Cochlear™ Nucleus® CI systems are designed to provide useful hearing. The system works by converting sound in the environment into electric pulses that stimulate the auditory nerve, allowing the brain to perceive sound. The Cochlear™ Nucleus® CI system has implanted and external components. Implanted component: The CI is surgically implanted under the skin behind the ear. It includes a receiver/stimulator to receive and decode the electrical signals from the sound processor and an electrode to deliver these signals to the cochlear. External components: The external components include a sound processor, and associated accessories and cables. The system is programmed by a Cochlear proprietary programming system, Custom Sound®.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in sentence in noise scores at 12 months post-activation in the binaural (CI and normal hearing (NH)) listening condition compared to preoperatively in the best listening (NH alone or NH and hearing aid) condition in 3 speaker configurations.Time frame: pre-implantation, 12 months post-activation
- Number of procedure and device related adverse events classified by type, frequency and severity.Time frame: 36 months post-activation
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Stanford University
Palo Alto, California
Rocky Mountain Ear Center
Englewood, Colorado
University of Iowa
Iowa City, Iowa
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.